Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cabaletta BioCABA +0.75%34 3-1 Month Momentum % is 2.71% as of Jul. 27, 2026. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,393 Biotechnology companies, Cabaletta Bio ranks better than 70.42% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-27), Cabaletta Bio's 3-1 Month Momentum % is 2.71%.
The industry rank for Cabaletta Bio's 3-1 Month Momentum % or its related term are showing as below:
CABA's 3-1 Month Momentum % is ranked better than 70.42% of 1393
companies
in the Biotechnology industry
Industry Median: -10.79
vs CABA: 2.71
Cabaletta Bio (NAS:CABA) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cabaletta Bio 3-1 Month Momentum % Related Terms
CABA vs SGMT, OVID, QTTB: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Cabaletta Bio's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cabaletta Bio 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cabaletta Bio's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cabaletta Bio's 3-1 Month Momentum % falls into.
Cabaletta Bio (NAS:CABA) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cabaletta Bio (CABA) has a 3-1 Month Momentum % of 2.71% as of Jul. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cabaletta Bio and its competitors. According to the industry distribution chart, Cabaletta Bio ranks #412 out of 1393 companies in the Biotechnology industry, placing it in the top 29.6%.
Is Cabaletta Bio's 3-1 Month Momentum % too high?
Cabaletta Bio's current 3-1 Month Momentum % is 2.71%. Based on the distribution chart, Cabaletta Bio ranks #412 out of 1393 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's 3-1 Month Momentum % compare to SGMT and OVID?
According to the Biotechnology industry distribution chart, Cabaletta Bio ranks #412 out of 1393 companies for 3-1 Month Momentum %. This puts Cabaletta Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cabaletta Bio and its competitors. Cabaletta Bio's current 3-1 Month Momentum % is 2.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current 3-1 Month Momentum % of 2.71%. The current 3-1 Month Momentum % is 2.71%. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current 3-1 Month Momentum % is 2.71% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score
Get the complete analysis for CABA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CABA has been successfully added to your 
